Skip to main content

Erectile Dysfunction

Erectile dysfunction (ED) is the consistent or recurrent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance.[1][2] It is one of the most common male sexual dysfunctions, affecting approximately 40% of men aged 40–49 and rising to 50–100% of men over 70.[1] Worldwide prevalence was projected to reach 322 million cases by 2025.[1][3]

For the operative treatment atlas (penile prosthesis, revascularization, Peyronie's surgery as comorbid disease) see Sexual Dysfunction Treatment Atlas. For the pharmacology hubs (PDE5 inhibitors, intracavernosal injection agents, intraurethral alprostadil, testosterone replacement, androgen adjuncts, priapism management) see Sexual Medicine & Andrology.

Pathophysiology​

Erection is a neurovascular event requiring coordination of psychological, endocrine, vascular, and neurological systems. Parasympathetic stimulation triggers release of nitric oxide (NO) from endothelial cells and nonadrenergic noncholinergic neurons, which activates guanylyl cyclase to produce cyclic GMP (cGMP). cGMP causes smooth-muscle relaxation in the corpora cavernosa, increasing arterial inflow and compressing subtunical venules to trap blood and produce rigidity. PDE5 inhibitors prolong this signal by blocking cGMP degradation.[1][4]

ED is classified as psychogenic, organic, or — most commonly — mixed:[1][2]

ClassMechanismExamples
VasculogenicArterial insufficiency, corporal veno-occlusive dysfunction (venous leak), sinusoidal fibrosisAtherosclerosis, post-radiation, post-traumatic
NeurogenicCentral or peripheral neural disruptionStroke, MS, spinal-cord injury, diabetic neuropathy, post–radical pelvic surgery
EndocrinologicalTestosterone, prolactin, thyroid axisHypogonadism, hyperprolactinemia, diabetes mellitus
Drug-inducedPharmacologic interference with NO / sympathetic balanceAntihypertensives, SSRIs, antiandrogens, major tranquilizers
PsychogenicPerformance anxiety, depression, relationship dynamics~ 20% of presentations[3][5]

Risk Factors​

Age is the dominant risk factor; type 2 diabetes mellitus is the second, with ED in 50–75% of diabetic men.[1] Other key contributors:[1][5][4]

  • Hypertension — ED prevalence up to 68%
  • Dyslipidemia
  • Obesity and metabolic syndrome
  • Sedentary lifestyle
  • Cigarette smoking — doubles ED prevalence vs nonsmokers
  • Alcohol and recreational drug use
  • Lower urinary tract symptoms / BPH
  • Depression
  • Prostate-cancer treatment — radical prostatectomy, radiation, brachytherapy

ED as a Cardiovascular Risk Marker​

ED and cardiovascular disease (CVD) share the same pathophysiology — endothelial dysfunction and atherosclerosis.[1][6] Because penile arteries are smaller-caliber than coronary arteries, the same degree of endothelial dysfunction manifests earlier in erectile tissues.

The Mostafaei 2021 umbrella review of meta-analyses confirmed that ED independently predicts:[7]

OutcomeRelative risk
Cardiovascular disease1.45
Coronary heart disease1.50
Myocardial infarction1.55
Stroke1.36
All-cause mortality1.25

More than two-thirds of patients with coronary artery disease have ED symptoms before the onset of coronary symptoms (Dong 2011 meta-analysis).[8][4] The Princeton III consensus recognizes ED as a strong predictor of CVD.[1] A new ED diagnosis should prompt cardiovascular risk assessment with the same seriousness as a new chest-pain syndrome.

Diagnostic Evaluation​

Evaluation begins with a thorough sexual, medical, and psychosocial history and a focused physical examination of the genitourinary, endocrine, vascular, and neurological systems.[9][10]

Validated questionnaire — IIEF-5 (Sexual Health Inventory for Men)​

ScoreSeverity
5–7Severe ED
8–11Moderate ED
12–16Mild-to-moderate ED
17–21Mild ED
22–25None

The IIEF-5 is the standard screening and outcomes-tracking instrument across ED trials and contemporary practice.[2]

Laboratory testing​

  • Fasting glucose / HbA1c — diabetes screen
  • Lipid panel — atherosclerotic risk
  • Morning total testosterone — repeat if abnormal; if low, add free testosterone and LH to differentiate primary vs secondary hypogonadism
  • Selected: prolactin, TSH when clinically indicated[9][10]

Specialized tests (selected cases)​

  • Nocturnal penile tumescence (NPT) — psychogenic vs organic differentiation
  • Intracavernosal injection (ICI) test — assesses vasculogenic component
  • Penile duplex Doppler ultrasound — peak systolic velocity (arteriogenic), end-diastolic velocity (veno-occlusive)
  • Cavernosometry / cavernosography — when surgical revascularization is being considered
  • Selective pudendal arteriography — pre-revascularization in young men with focal post-traumatic disease[9]

Cardiovascular risk assessment​

Given the strong CVD association, formal risk stratification (per the Princeton III consensus) is recommended for any new ED diagnosis.[1][11]

Treatment​

Treatment follows a stepwise, shared-decision-making approach anchored on the AUA 2018 guideline (Burnett, reaffirmed in subsequent amendments) and the 4th International Consultation on Sexual Medicine (ICSM 2015) framework.[12][13]

1. Lifestyle modification — the foundation​

The AUA guideline recommends counseling on tobacco cessation, regular exercise, weight loss, and improved control of diabetes, hypertension, and dyslipidemia. These interventions improve erectile function and overall cardiovascular health.[12][5]

2. First-line — oral PDE5 inhibitors​

PDE5 inhibitors are the first-line pharmacotherapy with overall efficacy of 60–70%.[1][12][13] See the PDE5 inhibitors pharmacology hub for the deep dive on mechanisms, dosing, contraindications, and post-RP rehab evidence.

AgentTypical dose
Sildenafil50–100 mg on demand
Tadalafil10–20 mg on demand, or 5 mg daily
Vardenafil10–20 mg on demand
Avanafil50–200 mg on demand

Key prescribing principles:

  • Try at least 4–6 times before deeming ineffective.[1][15]
  • Titrate to the maximum tolerated dose before escalating to second-line.[12][13]
  • Absolute contraindication: concurrent nitrate use — risk of severe hypotension.[14]
  • Caution with α-blockers (orthostatic hypotension) and patients with autonomic dysfunction.[15][14]
  • Common side effects: headache, flushing, dyspepsia, nasal congestion, visual disturbances.
  • No clinically significant efficacy difference among the four agents; choice is driven by patient preference (onset, duration, daily-vs-on-demand).[13]

3. Second-line therapies​

For PDE5 non-responders or those with contraindications:[12][16][17]

  • Intracavernosal injection (ICI) — alprostadil monotherapy or bimix / trimix / quadmix combinations. ICI is the most reliably effective non-surgical option in PDE5-resistant patients. Risks: priapism (~ 1.8% with alprostadil), injection-site pain, and penile fibrosis (4.5–13%). See the ICI agents pharmacology hub.
  • Intraurethral alprostadil (MUSE) — less invasive than ICI but typically less effective; useful when ICI is not tolerated. See intraurethral alprostadil.
  • Vacuum erection device (VED) — non-invasive, mechanical option particularly suitable for patients who cannot use pharmacotherapy or for post-RP penile-rehabilitation programs.

4. Third-line — penile prosthesis​

Surgically implanted inflatable or malleable penile prostheses are recommended when other treatments fail. Multicomponent inflatable prostheses (IPPs) achieve > 90% patient and partner satisfaction in contemporary series — among the highest satisfaction rates of any urologic prosthetic surgery.[12][10] Surgery should not be performed in the presence of active infection.[12]

For the operative pathway — preoperative evaluation (CURSED), intraoperative setup (no-touch), approaches (PS / IP / SC), reservoir placement (SoR / HSM), models database, infection prevention, revision, and complications — see Penile Implants.

5. Testosterone replacement therapy​

In men with confirmed hypogonadism (total testosterone < 300 ng/dL on two morning measurements with concordant symptoms), testosterone replacement improves IIEF erectile-function scores.[19][20] Benefit is greater in men with more severe hypogonadism (T < 250 ng/dL).[20] TRT may be combined with PDE5 inhibitors for enhanced effect in hypogonadal men with ED.[20][16]

The Endocrine Society 2018 guideline recommends baseline prostate-cancer risk assessment before initiation and monitoring for thromboembolism on therapy.[19] The TRAVERSE 2023 trial and the Bhasin & Snyder 2025 NEJM review clarified the contemporary cardiovascular safety profile (non-inferiority for MACE).[21] See the testosterone replacement pharmacology hub for the full framework.

6. Emerging therapies​

  • Low-intensity extracorporeal shockwave therapy (Li-ESWT) — proposed mechanism: neovascularization and tissue regeneration. The 2025 Cochrane review (Ergun) found evidence is still evolving with heterogeneous protocols and outcomes.[2][18]
  • Stem-cell and platelet-rich-plasma (PRP) therapy — investigational, targeting cavernosal-tissue repair. Currently outside guideline-supported practice.[18]

7. Psychosexual therapy​

Counseling is recommended for men with psychogenic ED, either as monotherapy or in combination with pharmacotherapy. Couples-based therapy is particularly valuable when relationship dynamics contribute.[5][14]

Special Populations​

PopulationKey considerations
Post-radical prostatectomyPenile rehabilitation with PDE5i (Sari Motlagh network meta + REACTT + Jo 2018 immediate start); MUSE, ICI, and VED as adjuncts; IPP for refractory cases
Post-pelvic radiationVasculogenic + neurogenic mechanism; PDE5i first-line; ICI / IPP for non-response
Diabetes mellitusHigh prevalence (50–75%); poorer PDE5i response; lower threshold for second-line[17]
Spinal-cord injury / MSNeurogenic mechanism; PDE5i first-line; autonomic-dysreflexia precaution in lesions T6 and above (see Autonomic Dysreflexia)[15]
Cardiovascular diseasePrinceton III risk stratification; nitrate use is an absolute contraindication to PDE5i[11]
Young men with focal post-traumatic diseaseSelective candidates for penile revascularization — see saphenous vein graft
Peyronie's disease overlapTreat ED with PDE5i first; surgical correction of curvature combined with IPP if both present — see Peyronie's disease

Prognosis and Key Takeaways​

ED is a treatable condition at all stages. The diagnosis should prompt cardiovascular risk assessment, as it may precede symptomatic CVD by several years (Dong 2011: > 2/3 of CAD patients have ED symptoms before coronary symptoms).[7][1][6][8]

A stepwise treatment approach — lifestyle modification → PDE5 inhibitors → ICI / MUSE / VED → penile prosthesis — allows most men to achieve satisfactory sexual function. Multicomponent IPP achieves > 90% patient and partner satisfaction in contemporary series, making the third-line step a high-yield rescue rather than a last resort.[12][10]

For the reconstructive urologist, ED management runs in parallel with penile-implant and Peyronie's-disease practice. A patient presenting with new-onset ED is a patient who needs both an operative algorithm in mind and a cardiology referral on the way out.

See Also​

References​

1. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–65. doi:10.1016/S0140-6736(12)60520-0

2. Ergun O, Kim K, Kim MH, et al. Low-intensity shockwave therapy for erectile dysfunction. Cochrane Database Syst Rev. 2025;7:CD013166. doi:10.1002/14651858.CD013166.pub3

3. Lee HW, Lee MS, Kim TH, et al. Ginseng for erectile dysfunction. Cochrane Database Syst Rev. 2021;4:CD012654. doi:10.1002/14651858.CD012654.pub2

4. McVary KT. Erectile dysfunction. N Engl J Med. 2007;357(24):2472–81. doi:10.1056/NEJMcp067261

5. Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820–7.

6. Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65(5):968–78. doi:10.1016/j.eururo.2013.08.023

7. Mostafaei H, Mori K, Hajebrahimi S, et al. Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses. BJU Int. 2021;128(1):3–11. doi:10.1111/bju.15313

8. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85. doi:10.1016/j.jacc.2011.06.024

9. Lee H, Hwang EC, Oh CK, et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024;1:CD013071. doi:10.1002/14651858.CD013071.pub2

10. McMahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust. 2019;210(10):469–76. doi:10.5694/mja2.50167

11. Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nat Rev Cardiol. 2022;19(1):59–74. doi:10.1038/s41569-021-00593-6

12. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–41. doi:10.1016/j.juro.2018.05.004

13. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465–88. doi:10.1016/j.jsxm.2016.01.016

14. Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion. Fertil Steril. 2023;120(5):967–72. doi:10.1016/j.fertnstert.2023.07.001

15. Hentzen C, Musco S, Amarenco G, Del Popolo G, Panicker JN. Approach and management to patients with neurological disorders reporting sexual dysfunction. Lancet Neurol. 2022;21(6):551–62. doi:10.1016/S1474-4422(22)00036-9

16. Lee M, Sharifi R. Non-invasive management options for erectile dysfunction when a phosphodiesterase type 5 inhibitor fails. Drugs Aging. 2018;35(3):175–87. doi:10.1007/s40266-018-0528-4

17. Hatzimouratidis K, Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014;14(11):545. doi:10.1007/s11892-014-0545-6

18. Wang CM, Wu BR, Xiang P, Xiao J, Hu XC. Management of male erectile dysfunction: from the past to the future. Front Endocrinol. 2023;14:1148834. doi:10.3389/fendo.2023.1148834

19. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–44. doi:10.1210/jc.2018-00229

20. Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on International Index of Erectile Function scores. Eur Urol. 2017;72(6):1000–11. doi:10.1016/j.eururo.2017.03.032

21. Bhasin S, Snyder PJ. Testosterone treatment in middle-aged and older men with hypogonadism. N Engl J Med. 2025;393(6):581–91. doi:10.1056/NEJMra2404637